Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C

Cancer Research

Volumn 58, Issue 24, 1998, Pages 5850-5858

  Rabindran, Sridhar K ^a   He, Haiyin ^a   Singh, Maya ^a   Brown, Eileen ^a,b   Collins, Karen I ^a   Annable, Tami ^a   Greenberger, Lee M ^a  

^a PFIZER INC   (United States)

^b PERKINELMER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BISANTRENE; CAMPTOTHECIN; CL 329753; CL 329763; COLCHICINE; DOXORUBICIN; ETOPOSIDE; FUMITREMORGIN C; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MYCOTOXIN; PACLITAXEL; PROTEIN INHIBITOR; RNA; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; HUMANS; INDOLES; MITOXANTRONE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; TUMOR CELLS, CULTURED;

EID: 0032535004     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Young, R. C. Drug resistance: the clinical problem. In: R. F. Ozols (ed.), Drug Resistance in Cancer Therapy, pp. 1-12. Boston: Kluwer Academic Press, 1989.
2. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem.,62: 385-427, 1993.
3. Greenberger, L. M., Cohen, D., and Horwitz, S. B. In vitro models of multiple drug resistance. In: L. J. Goldstein and R. F. Ozols (eds.), Anticancer Drug Resistance, pp. 69-106. Norwell, MA: Kluwer Academic Publishers, 1994.
4. Gottesman, M. M., Michisch, G. H., and Pastan, I. In vivo models of P-glycoprotein-mediated multidrug resistance. In: L. J. Goldstein and R. F. Ozols (eds.), Anticancer Drug Resistance, pp. 107-128. Norwell, MA: Kluwer Academic Publishers, 1994.
5. Sikic, B. I., Fisher, G. A., Lum, B. L., Brophy, N. A., Yahanda, A. M., Adler, K. M., and Halsey, J. Clinical reversal of multidrug resistance. In: L. J. Goldstein and R. F. Ozols (eds.), Anticancer Drug Resistance, pp. 149-165. Norwell, MA: Kluwer Academic Publishers, 1994.
6. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S. L., Gazdar, A., Pirker, R., Cossman, J. Gottesman, M. M., and Pastan, I. Expression of multidrug resistance gene in human cancers. J. Natl. Cancer Inst. (Bethesda), 81: 116-124, 1989.
7. Arceci, R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81: 2215-2222, 1993.
8. Goldstein, L. J. Clinical reversal of drug resistance. Curr. Prob. Cancer, 19: 65-124, 1995.
9. Baas, R., Jongsma, A. P. M., Broxterman, H. J., Arceci, R. J., Housman, D., Scheffer, G. L., Riethorst, A., van Groenigen, M., Nieuwint, A. W. M., and Joenje, H. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res.,50: 5392-5398, 1990.
10. Brock, I., Hipfner, D. R., Nielsen, B. S., Jensen, P. B., Deeley, R. G., Cole, S. P. C., and Schested, M. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP16 (etoposide)-selected H69 small cell cancer cells. Cancer Res., 55: 459-462, 1995.
11. Faulds, D., Balfour, J. A., Chrisp, P., and Langtry, H. D. Mitoxantrone. Drugs, 41: 400-449, 1991.
12. Bow, E. J., Sutherland, J. A., Kilpatrick, M. G., Williams, G. J., Clinch, J. J., Shore, T. B., Rubinger, M., and Schacter, B. A. Therapy of untreated acute myeloid leukemia in the elderly: remission induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J. Clin. Oncol.,14: 1345-1352, 1996.
13. Cowan, J. D., Neidhart, J., McClure, S., Coltman, C. A., Jr., Gumbart, C., Martino, S., Hutchins, L. F., Stephens, R. L., Vaughan, C. B., and Osborne, C. K. Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J. Natl. Cancer Inst. (Bethesda), 83: 1077-1084, 1991.
14. Tannock, I. F., Osaoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M. L., and Murphy, K. C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol.,14: 1756-1764, 1996.
15. Durr, F. E., Wallace, R. E., and Citarella, R. V. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat. Rev.,10: 3-11, 1983.
16. Zhang, X. P., Ritke, M. K., Yalowich, J. C., Slovak, M. L., Ho, J. P., Collins, K. I., Annable, T., Arceci, R. J., and Greenberger, L. M. P-glycoprotein mediates profound resistance to bisantrene. Oncol. Res.,6: 291-301, 1994.
17. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res.,54: 5902-5910, 1994.
18. Zaman, G. J. R., Flens, M. J., van Leusden, M. R., de Haas, M., Mulder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F., Broxterman, H. J., and Borst, P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA, 91: 8822-8826, 1994.